

DAFTAR PUSTAKA

- Alfonso, Q., Hagop, K., Jones, D., Jianqin, S., Gautam, B., Deborah, T., Steven K., *et al.*, 2009. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. *Blood*. First Edition paper, April 15.
- Anonim., 2001. Gleevec Highlights Of Prescribing Information. Novartis Pharmaceuticals Corporation.
- Arber, D., Attilio, O., Hasserjian, R., Jurgen, T., Borowitz, J., Beuet, M., *et al.*, 2016. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* First Edition paper. April 11.
- Arora, A., and Eric, M., 2005. Role Of Tyrosine Kinase Inhibitors In Cancer Therapy. *The Journal Of Pharmacology And Experimental Therapeutics*. Vol. 315. No. 3
- Baccarani M, Saglio G, Goldman J, Andreas, H., Soverini, S., Apperley, *et al.*, 2006. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*.108:1809-1820.
- Baccarani, M., Andreas, H., Soverini, S., Apperley, J., O'Brien, S., Elias, J., Carlos G., *et al.*, 2012. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 23 (Supplement 7): vii72–vii77.
- Baccarani, M., Michael, W., Gianantonio, R., Andreas, H., Soverini, S., Apperley, J., *et al.*, 2013. European Leukemia Net recommendations for the management of chronic myeloid leukemia. *Blood*. First Edition paper. June 26.
- Balatzenko, G., Vundinti, B., Margarita, G., 2011. Correlation between the type of BCR-ABL transcripts and blood cell counts in chronic myeloid leukemia a possible influence of MDR1 gene expression. *Hematology Reports* 3 :e3.
- Charles, L., Andreas, H., Eric, F., Goldman, M., Carole, B., Miller, T., Oliver, G., Ottmann, C., Schiffer, M., *et al.*, 2002., Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood*. Volume 99. Number 10.
- Chasseriau, J., Jerome, R., Frederic, B., Jean-Claude, C., Guilhot, F., Bourmeyster, N., *et al.*, 2004. Characterization of the Different BCR-ABL Transcripts with a Single Multiplex RT-PCR., *Journal of Molecular Diagnostics*. Vol. 6. No. 4.
- Dahlan, S., 2012. Membuat proposal penelitian bidang kedokteran dan kesehatan. Sagung Seto. Jakarta.
- Deininger, M., John, M., Goldman, R., Junia, V., 2000, The molecular biology of chronic myeloid leukemia. *Blood Journal*, VOL 96, No 10.
- Deininger, M., O'Brien, S., Guilhot, F., 2009. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low

- risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. *Blood*.114(22): Abstract 21126.
- Djatmiko, A., Octovionus, J., Fortunata, Novina., 2013. Profil Cancer Delay pada Kasus Kanker Payudara di RS Onkologi Surabaya. *Indonesian Journal of Cancer*, [S.l.], v. 7, n. 2, Juni
- Dupont WD, Plummer WD: "Power and Sample Size Calculations: A Review and Computer Program", *Controlled Clinical Trials* 1990; 11:116-28.
- Erdem, F dan Bilen, Y., 2012. Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey. *Turk J Med Sci* ; 42 (1): 31-38
- Fadjari, H dan Sukrisman, L., 2014. Leukemia Granulositik Kronik. Dalam: Sudoyo Aru. W., Setyoyahadi Bambang., Alwi Idrus., Simadibrata Marcelus. K., Setiati Siti (editor). *Buku Ajar Ilmu Penyakit Dalam*. Pusat penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Indonesia Jakarta. edisi VI. Jilid II.
- Groffen, J., Stephenson, J., Heisterkamp, N., Klein, A., Bartram, C., Grosveld, G. *et al.*, 1994. Philadelphia chromosomal breakpoints are clustered within a limited region, BCR on chromosome 22. *Cell* ;36(1):93-99.
- Han, X., Jenny, S., Jacob, D., Randa, S., Hillis, C., Maria, H., *et al.*, 2016. Gender and BCR ABL transcript type are correlated with molecular response to imatinib treatment in patients with CML. *European Journal Of Hematology*. Volume 96. issue 4.
- Hanfstein, B., Michael, L., Rudiger, H., Susanne, S., Philipp, E., Christian, D., Alice, F., Ulrike, P., 2014, Distinct characteristics of e13a2 *versus* e14a2 *BCR-ABL1* driven chronic myeloid leukemia under first-line therapy with imatinib, doi:10.3324/haematol.2013.096537
- Harrianto, R., Ardian, B., Satyadi, V., Samara, D., Nuryani, S., Tjhin, P., Magdalena, W., 2002, Karakteristik dimensi antropometrik statis mahasiswa Fakultas Kedokteran Universitas Trisakti usia 19 - 21 tahun. *J Kedokteran Trisakti*. Vol 23. No.3.
- Harryanto, A., Hilman, T., Ikhwan, R., Arif, W., 2011, Clinical Characteristic, Hematologic Response and Gene Mutation of Patients with Chronic Phase Chronic Myeloid Leukemia (CML) to Imatinib at Cipto Mangunkusumo National Hospital. *Indonesian Journal of Cancer* Vol 5. No 4
- Kantarjian, H., Charles, S., Awyers, M., Andreas, H., Hochhaus, D., Francois, G., Chiffer, C. 2002. Hematologic and cytogenetic responses to imatinib mesylate In chronic myelogenous leukemia. *New England Journal Medicine*, Vol. 346, No. 9
- Langabeer, S., 2013. Is the BCR-ABL1 transcript type in chronic myeloid leukemia relevant? *Med Oncol.*;30(2):508.
- Li, S., Ilaria, R., Million, R., Daley, G., Etten, R., Linda, V., *et al.*, 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. *J Exp Med.*;189(9):1399-1412.

- Lindsey, A., Torre, M., Freddie, B., Rebecca, L., Siegel, M., Ferlay, J., *et al.*, 2015. Global Cancer Statistics. *C.A. Cancer. J. Clin.*65:87-108.
- Lucas, C., Robert, J., Harris, A., Andrea, D., Katy K., Sarah, J., Lihui, W., *et al.*, 2009. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients. *Haematologica*.009134.
- Made, B., Renny, A., Ketut, S., 2015. Respon hematologi pasien leukemia mieloid kronik yang mendapat pengobatan tyrosine kinase inhibitor selama setahun di RSUP Sanglah Denpasar. <https://ojs.unud.ac.id/index.php/eum/article/view/20920/13710>
- Martin, S., and James, D. G., 2001. Mechanisms Of Transformation By The BCR/ABL Oncogene. *International Journal Of Hematology. Int J Hematol*;73:278-291.
- Melo, J. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. *Blood*; 88(7):2375-2384.
- O'brien, S., Jerald, P., Camille., N., Devine, S., Fathi, A., Gotlib, Jason., *et al.*, 2014. Chronic Myeloid Leukemia, NCCN Clinical Practice Guideline In Oncology., version 3.2014.
- Preetesh, J., Hagop, K., Aziz, N., O'Brien, S., Elias, J., Carlos G., *et al.*, 2013. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities, *The American Society of Hematology. Blood.* 25 April, Volume 121.
- Prejzner, W., 2002. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostik indexes and survival in patients with chronic myeloid leukemia. *Med Sci Monit*; 8(5): BR193-197
- Preteesh, J., Hagop, K., Keyur, P., Graciela, N., Gonzalez, T., Rajyalakshmi, L., Rashmi K., Koji, S., Elias, J., *et al.*, 2016. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. *The American Society of Hematology. Blood.* 10 March. Volume 127. Number 10.
- Rizzieri, D and, Moore J., 2012. Implementation of Management Guidelines For Chronic Myeloid Leukemia. Vol. 37 No. 11.
- Sharma, P., Kumar, L., Sujata, M., Vinod, K., 2010. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. *Ann Hematol* 89:241–247
- Skorski, T., 2007, Genomic Instability: The Cause and Effect of BCR/ABL Tyrosine Kinase. *Current Hematologic Malignancy Reports.* 2:69–74
- Verma, D., Hagop, M., Jones, D., Rajyalakshmi, L., Borthakur, G., , 2009. Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostik significance. *Blood.* 10 September. Volume 114. Number 11.
- Vlahovic, G., 2003. Activation of Tyrosine Kinases in Cancer. *The Oncologist* 8; 531-538.

- Wang, L., Lucas, C., Austin, G., Knight, K., Watmough, J., Shwe, H., Dasgupta, R., Nauman, M., Butt, D., Galvani, C., 2010. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. *Leukemia* 22, 1963–1966; doi:10.1038/leu.2008.225.
- Wetzler, M., Guido, M., Clara, D., 2012. Acute and Chronic Myeloid Leukemia In: Kasper, D, Fauci, L., Longo, L., Jameson, L., Loscalzo, J., *et al* (Editors) *Harrison's Principles of Internal Medicine, the 18th edition*, The McGraw-Hill Companies, Chapter 109.
- Xiamin, G., Yong Z, Jinlan, P., 2015. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostik significance. *Leuk Lymphoma*. 56(12): 3343-3347.